Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study

類似資料

• Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
  著者:: Chen, Wen-Chun, 等
  出版事項: (2017)
• Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
  著者:: William, William N., 等
  出版事項: (2018)
• Single Agent Irinotecan for the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
  著者:: J Gilbert, 等
  出版事項: (2007-01-01)
• Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
  著者:: Trieu, Vanessa, 等
  出版事項: (2018)
• The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience
  著者:: Yeh, Tsung-Jang, 等
  出版事項: (2021)